Osteoporosis News

After one hip fracture, compliant users of bisphosphonates are less likely to undergo a second hip fracture than nonusers, according to results of this study.

SAN FRANCISCO — Doubling of insulin resistance was associated with a 10% to 14% decrease in bone strength among participants in the Biomarker Project of the Midlife in the United States Study.

SAN FRANCISCO — High sodium intake is associated with an increased risk for non-vertebral fractures in postmenopausal women, independent of age, BMI, bone mineral density, muscle strength and balance ability, according to data presented here.

SAN FRANCISCO — High sodium intake is associated with an increased risk for non-vertebral fractures in postmenopausal women, independent of age, BMI, bone mineral density, muscle strength and balance ability, according to data presented here.

Findings of a recently published retrospective study indicate that patients who undergo lumbar epidural steroid injections may be at increased risk for vertebral fractures.

Results from a randomized, open-label, active comparator, phase 3 controlled study demonstrate that a recombinant human parathyroid hormone analog significantly increased lumbar spine volumetric bone mineral density compared with a bisphosphonate in men with glucocorticoid-induced osteoporosis.

Despite a high prevalence of vitamin D deficiency among senior populations, researchers of this study found that about 20% received vitamin D supplements after hip fracture.

Researchers in this study found that post-traumatic ulna plus variance greater than 2 mm was the only factor significantly associated with poor outcome when analyzing a cohort of young patients with unilateral distal radius fractures who were not yet at risk for osteoporosis.

Researchers in this study identified low bone mineral density, low body mass index and intradiscal cement leakage as risk factors for an osteoporotic vertebral compression fracture after vertebroplasty.

Results from a randomized controlled trial suggest that combination denosumab and teriparatide was superior to either agent alone at increasing bone mineral density and led to greater improvements than previously reported with any other treatments approved for osteoporosis.